Our mission, vision & values.

As an organization that endeavors to improve healthcare for all, every choice we make is driven by our mission: to better serve patients by accelerating and innovating health care through approaches that challenge the status quo of science and care.

The culmination of our daily efforts guides our long-term vision: to improve human health for all through personalized medicine by bridging the gap between research and care.

Our core foundational values of integrity, collaboration, transparency, and innovation form the basis of who we hire, how we operate, and everything we believe.


A leap in cancer research born from collaboration between scientists and entrepreneurs.

QLHC Leadership

Our company founders had seen it time and again: good ideas and research projects in University settings were often “orphaned” at the end of a research project leaving them with no funds or organizations structure to adequately engage clinical providers leaving valuable IP undeveloped. The kind of IP that could radically change patient care. So, in 2005, we were created as a collaboration between medical researchers at University of California, San Francisco and Silicon Valley entrepreneurs to change what cancer research and clinical trials could be.
Play Video

Working at QLHC

Taking giant leaps to defeat cancer wouldn’t be possible without a world-class team of thinkers from a diverse and unique set of backgrounds who make up our team. Discover all the reasons people love working at QLHC along with our latest open roles.

QLHC Media Relations

For all media related questions and inquiries, please contact Jacqueline Murray.

QLHC Financial Reports

View our financial history including audit reports, form 990’s, and donations.


2020 Form 990


2020 Form 990


2020 Form 990


2020 Form 990

QLHC in the News

Discover all the latest ways our leap is making a positive impact.

40-site U.S. trial enrolling more than 300 patients could significantly change the way DCIS is treated and reduce possibly unnecessary surgery
After years of watching women diagnosed with the disease get the same, drastic treatment of disfiguring surgery or brutal chemotherapy and radiation, Esserman believed doctors not only could but should be able to do better.
Quantum Leap Healthcare Collaborative™ today announced that Arvinas’ vepdegestrant (ARV-471), a novel PROTAC® estrogen receptor (ER) protein degrader being co-developed with Pfizer Inc. will be evaluated in the ongoing I-SPY TRIAL endocrine program sponsored by Quantum Leap.
Quantum Leap Healthcare Collaborative (QLHC) announces the mobile responsive launch of its metastatic breast cancer clinical trial matching service, Metastatic Trial Search (MTS). This launch expands MTS's reach to a broader range of breast cancer patient groups with a goal of reaching a more diverse population including those under-represented in clinical trials.
Contact Us
Investigators Portal
QLHC in the News
Working at QL
Contact Us